Latent infection with tuberculosis affects approximately 30% of the world population and is among the commonest and most serious opportunistic bacterial infections in the immunocompromised, particularly those infected with HIV. Despite the decline in incidence of active disease in industrialised countries, the advent of novel immunosuppressive therapies targetting mechanisms central to control of latent tuberculosis infection has highlighted the need for effective screening in high-risk populations. While attention has focused on the risk associated with anti-TNF alpha biologic therapies, few longitudinal studies have addressed risk stratification for other forms of immunosuppression. Interferon-gamma release assays appear to offer better diagnostic performance than traditional tuberculin skin-testing but their interpretation needs to be considered carefully in terms of epidemiological and clinical context. Chemoprophylaxis for latent infection based on isoniazid is not free of risk of hepatotoxicity especially in patients with multiple comorbidities. Recent meta-analyses and clinical trials have identified a number of new options for chemoprophylaxis with shorter and possibly safer regimens. Disclosures: The author has declared no conflicts of interest.
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I056 TRAVELLING AND RHEUMATIC DISEASES
Lisa Ford 1 1 National Travel Health Network and Centre, Liverpool School of Tropical Medicine, Liverpool, UNITED KINGDOM There were 70.8 million visits overseas by UK residents in 2016. Many of these travellers will have co-morbidities that may change the necessary travel health advice typically provided to travellers going to some destinations or sometimes require a change to the chosen destination. During this presentation, reliable travel health internet resources and the service provided by National Travel Health Network and Centre health professional telephone advice line service will be highlighted. Using queries to the advice line to illustrate the typical challenges faced, the current literature will be considered which informs pre-travel health decisions made for and with travelers with rheumatic diseases. Disclosures: The author has declared no conflicts of interest. Background: Lupus is a chronic, multisystem, autoimmune disease of unknown aetiology affecting predominantly young women of reproductive age. The condition affects individuals' physical, psychological and social health with resultant limitations of physical functioning and disrupted social life. Though common in women of black ancestry in Europe and the United States of America, lupus is believed to be rare in black Africans. There is a paucity of data on living with and the management of lupus from the African continent. Aim: To explore patients' perspectives of living with lupus in Kenya. Methods: A qualitative study that drew on the principles of constructivist grounded theory approach was conducted between August 2013 and June 2015 in two rheumatology clinics in Nairobi. Purposive and theoretical sampling techniques were employed. Data were collected through in-depth face to face interviews using an interview guide with open-ended questions. Interviews were transcribed verbatim and inductively analysed using the constant comparative method. Findings: Twenty-one patients aged between 19 to 56 years with a disease duration ranging between 2 to 7 years were identified. The individuals' perspectives revealed that living with lupus in Kenya was full of challenges. Five interrelated categories explained the perspectives of the participants: naming the illness; cultural beliefs, practices and prejudices; going round the system; resources for managing life with lupus and a shadow of myself. Diagnosing lupus was difficult in Kenya due to various health system deficiencies. Some patients delayed initial help-seeking. Some patients also had beliefs regarding supernatural causation of the condition, due to a lack of understanding about the illness, with resultant use of traditional remedies and experience of stigma from those around them. The findings also revealed that lupus care was costly and difficult to access due: healthcare funding structure in Kenya, inadequate resources, lack of integrated care and some patient related factors, like lack of economic and social resources. Families bore a heavy burden in terms of economic and social resources. The illness disrupted patients' lives in various ways. However, they attempted to reconstruct the disruptions with variable success. Conclusion: Data from the patients revealed that living with lupus in Kenya is full of challenges. Understanding structural and social processes which influence the experiences may assist with informing future strategies that can be utilised to improve the care and experience of patients with lupus. Disclosures: The author has declared no conflicts of interest.
I057 FEVERS IN THE RECENTLY ARRIVED TRAVELLER

I061 WORK AS A HEALTH OUTCOME: IMPACT OF DISEASE ON ABILITY TO WORK AND OF WORK ON PATIENT WELL-BEING
Debbie Cohen 1 1 School of Medicine, Cardiff University, Cardiff, UNITED KINGDOM The presentation will focus on 'work as a health outcome' and recent research in this area. The aim will be to raise awareness of the importance of work in everyday practice for rheumatologists and their patients. It will offer some practical solutions for incorporating simple messages for training rheumatology teams and ways to potentially incorporate these messages into everyday practice when assessing patients' needs. Disclosures: D.C. has been funded by AbbVie for research projects.
I062 VOCATIONAL REHABILITATION AND THE ARMED SERVICES
John Etherington 1 1 Defence Medical Rehabilitation Centre, Headley Court, Epsom, UNITED KINGDOM This presentation will address the approach taken by the Armed Forces to maximise the vocational outcome of patients with musculoskeletal conditions. This involves the use of a multi-disciplinary bio-psychosocial model of care, including exercise-based rehabilitation, in combination with standard pharmacotherapy. Setting high expectations of vocational outcomes helps to drive global clinical improvements. Disclosures: The author has declared no conflicts of interest.
